The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of TGF-β responsive signature with anti-tumor effect of vactosertib, a potent, oral TGF-β receptor type I (TGFBRI) inhibitor in patients with advanced solid tumors.
 
Vicki Leigh Keedy
Employment - Zimmer BioMet (I)
Consulting or Advisory Role - Janssen Oncology; Karyopharm Therapeutics; Threshold Pharmaceuticals
Research Funding - Advenchen Laboratories (Inst); BioMed Valley Discoveries (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Lilly (Inst); medpacto (Inst); pfizer (Inst); Plexxikon (Inst); Roche (Inst); Threshold Pharmaceuticals (Inst); TRACON Pharma (Inst)
 
Todd Michael Bauer
Employment - Sarah Cannon Research Institute; Tennessee Oncology
Consulting or Advisory Role - Guardant Health; Ignyta (Inst); Loxo; Moderna Therapeutics (Inst); Pfizer
Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Immunocore (Inst); Immunogen (Inst); Incyte (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); MabVax (Inst); MedImmune (Inst); medpacto (Inst); Merck (Inst); Merrimack (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Peleton (Inst); Pfizer (Inst); Principa Biopharma (Inst); Principa Biopharma (Inst); Roche (Inst); Sanofi (Inst); Stemline Therapeutics (Inst)
 
Jeffrey Melson Clarke
Consulting or Advisory Role - Inivata; Premier, Inc.
Speakers' Bureau - Guardant Health; Merck
Research Funding - Abbvie; Adaptimmune; Bristol-Myers Squibb; Genentech/Roche; medpacto; Moderna Therapeutics; Spectrum Pharmaceuticals
 
Herbert Hurwitz
Honoraria - Genentech/Roche; Lilly/ImClone
Consulting or Advisory Role - Acceleron Pharma; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; Incyte; Lilly; Novartis; OncoMed; TRACON Pharma
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Macrogenics (Inst); NCI (Inst); Novartis (Inst); Regeneron (Inst); TRACON Pharma (Inst)
 
Insun Baek
Employment - medpacto
Stock and Other Ownership Interests - medpacto
Travel, Accommodations, Expenses - medpacto
 
Ilho Ha
Employment - medpacto
Stock and Other Ownership Interests - medpacto
Patents, Royalties, Other Intellectual Property - Patents
 
Chan-Young Ock
Employment - medpacto
Stock and Other Ownership Interests - medpacto
 
Su Youn Nam
Employment - ImmuneOncia; Yuhan
Leadership - medpacto
Stock and Other Ownership Interests - medpacto
Consulting or Advisory Role - medpacto
Travel, Accommodations, Expenses - medpacto
 
Mina Kim
No Relationships to Disclose
 
Neunggyu Park
No Relationships to Disclose
 
Jung Yong Kim
No Relationships to Disclose
 
Seong-Jin Kim
Employment - medpacto; medpacto (I); Theragen Etex
Leadership - medpacto; Theragen Etex
Stock and Other Ownership Interests - BiSiChem; medpacto; medpacto (I); Theragen Etex; Theragen Etex (I)
Patents, Royalties, Other Intellectual Property - Korea Research Institute of Chemical Technology
Travel, Accommodations, Expenses - medpacto; medpacto (I); Theragen Etex